NeuroRx Announced that RLF-100(TM) has Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure among Patients with Severe Covid-19 Treated with HFNO at 28 Day Interim Endpoint

Rhea-AI Summary

Relief Therapeutics announced updates on its lead compound RLF-100(TM) (aviptadil), which is in advanced clinical trials for treating respiratory failure in critical COVID-19 patients. Data from a Phase 2b/3 trial, managed by NeuroRx, indicates that RLF-100(TM) has shown promising results, significantly accelerating patient recovery. The company holds various patents for the drug and focuses on clinical-stage programs for respiratory diseases. It is publicly traded under the symbols RLF in Switzerland and RLFTF in the U.S.

Positive

• RLF-100(TM) has shown accelerated recovery in Phase 2b/3 trials for COVID-19 respiratory failure.
• Relief holds patents for RLF-100(TM) and focuses on developing treatments for respiratory diseases.

Negative

• Forward-looking statements indicate uncertainty regarding future trial results and regulatory approvals.

GENEVA, SWITZERLAND / ACCESSWIRE / February 24, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in advanced clinical development, announces that NeuroRx, Inc. has reported data from the Phase 2b/3 trial of RLF-100(TM) for the treatment of Respiratory Failure in Critical COVID-19 patients. NeuroRx is solely responsible for clinical development and regulatory submissions related to RLF-100(TM) in the U.S.

The relevant NeuroRx press release can be found here.

###

ABOUT RELIEF

Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100^TM (aviptadil) is being investigated in two placebo-controlled U.S. late-stage clinical trials in respiratory deficiency due to COVID-19. Relief holds a patent issued in the United States and various other countries covering potential formulations of RLF-100^TM.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.

www.relieftherapeutics.com

CORPORATE CONTACT: RELIEF THERAPEUTICS Holding AG Raghuram (Ram) Selvaraju, Ph.D., MBA Chairman of the Board Mail: contact@relieftherapeutics.com www.relieftherapeutics.com
MEDIA AND INVESTOR CONTACTS: MC Services AG Anne Hennecke / Brittney Sojeva Tel.: +49 (0) 211-529-252-14 Mail: relief@mc-services.eu

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG. The results reported herein may or may not be indicative of the results of future and larger clinical trials for the treatment of respiratory failure from COVID-19 or other respiratory diseases. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements do not constitute guarantees of future performance and are subject to a variety of risks and uncertainties, including whether the results described herein will be sufficient to gain any regulatory approvals for RLF-100(TM). RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and do not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SOURCE: Relief Therapeutics Holdings AG

View source version on accesswire.com:
https://www.accesswire.com/631604/NeuroRx-Announced-that-RLF-100TM-has-Demonstrated-Ten-Day-Accelerated-Recovery-from-Respiratory-Failure-among-Patients-with-Severe-Covid-19-Treated-with-HFNO-at-28-Day-Interim-Endpoint

FAQ

What are the latest results for RLF-100(TM) in COVID-19 treatment?

RLF-100(TM) has demonstrated ten-day accelerated recovery from respiratory failure in severe COVID-19 patients during its Phase 2b/3 trials.

What is the significance of the Phase 2b/3 trial for RLF-100(TM)?

The Phase 2b/3 trial's results are crucial as they may indicate the effectiveness of RLF-100(TM) in gaining regulatory approvals.

What is Relief Therapeutics' focus in drug development?

Relief Therapeutics focuses on clinical-stage programs, particularly developing treatments for respiratory diseases.

Under which stock symbols is Relief Therapeutics traded?

Relief Therapeutics is listed on the SIX Swiss Exchange under RLF and on the OTCQB in the U.S. under RLFTF.

What risks are associated with RLF-100(TM) according to the press release?

Risks include uncertainties related to the efficacy of RLF-100(TM) in larger trials and challenges in obtaining regulatory approvals.